Evaluation and management of dyslipidemia in patients with HIV infection

Journal of General Internal Medicine

Volumn 17, Issue 10, 2002, Pages 797-810

  Green, Michael L ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b St Mary Hospital   (United States)

Author keywords

HAART; HIV; Hyperlipidemia; Lipodystrophy; Protease inhibitors; Triglycerides

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; CYCLOSPORIN; DELAVIRDINE; EFAVIRENZ; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; INDINAVIR; ITRACONAZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MEVINOLIN; NELFINAVIR; NEVIRAPINE; NICOTINIC ACID; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SIMVASTATIN; STAVUDINE; TRIACYLGLYCEROL; TROGLITAZONE; UNINDEXED DRUG;

CHOLESTEROL BLOOD LEVEL; CHYLOMICRONEMIA SYNDROME; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS; DIET; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DYSLIPIDEMIA; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INCIDENCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPODYSTROPHY; LIPOSUCTION; LYMPHOCYTE COUNT; MEDICAL DECISION MAKING; METABOLIC DISORDER; PANCREATITIS; PREVALENCE; REVIEW; RISK FACTOR; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ANTILIPEMIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; HYPERLIPIDEMIAS;

EID: 0036404783     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1497.2002.20201.x     Document Type: Review

References (129)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. [see comments]. N Engl J Med. 1997;337:725-33.
2. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-9.
3. Palella FJ Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. [see comments]. N Engl J Med. 1998;338:853-60.
4. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. [see comments]. Lancet. 1999;353:2093-9.
5. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study. Arch Intern Med. 2000;160:2050-6.
6. Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS. 2001;15:231-9.
7. Constans J, Pellegrin JL, Peuchant E, et al. Plasma lipids in HIV-infected patients: A prospective study in 95 patients. Eur J Clin Invest. 1994;24:416-20.
8. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045-52.
9. Zangerle R, Sarcletti M, Gallati H, Reibnegger G, Wachter H, Fuchs D. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr. 1994;7:1149-56.
10. Garg A. Lipodystrophies. Am J Med. 2000;108:143-52.
11. Echevarria KL, Hardin TC, Smith JA. Hyperlipidemia associated with protease inhibitor therapy. Ann Pharmacother. 1999;33:859-63.
12. Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS. 1997;11:938-9.
13. Pujol RM, Domingo P, Xavier Matias G, et al. HIV-1 protease inhibitor-associated partial lipodystrophy: Clinicopathologic review of 14 cases. J Am Acad Dermatol. 2000;42:193-8.
14. Panse I, Vasseur E, Raffin-Sanson ML, Staroz F, Rouveix E, Saiag P. Lipodystrophy associated with protease inhibitors. Br J Dermatol. 2000;142:496-500.
15. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999;13:F63-70.
16. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-8.
17. Koppel K, Bratt G, Eriksson M, Sandstrom E. Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection. Int J STD AIDS. 2000;11:451-5.
18. Garcia-Benayas T, Blanco F, de la Cruz JJ, et al. Role of nonnucleosides in the development of HAART-related lipid disturbances. J Acquir Immune Defic Syndr. 2001;28:496-8.
19. Manfredi R, Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: Frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J Infect. 2001;42:181-8.
20. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort study. Circulation. 1999;100:700-5.
21. Roge BT, Katzenstein TL, Gerstoft J. Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir. Scand J Infect Dis. 2001;33:306-11.
22. Roberts AD, Muesing RA, Parenti DM, Hsia J, Wasserman AG, Simon GL. Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients. Clin Infect Dis. 1999;29:441-3.
23. Vergis EN, Paterson DL, Wagener MM, Swindells S, Singh N. Dyslipidaemia in HIV-infected patients: Association with adherence to potent antiretroviral therapy. Int J STD AIDS. 2001;12:463-8.
24. Thiebaut R, Dabis F, Malvy D, Jacqmin-Gadda H, Mercie P, Valentin VD. Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998. Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA). J Acquir Immune Defic Syndr. 2000;23:261-5.
25. Boufassa F, Dulioust A, Lascaux AS, et al. Lipodystrophy in 685 HIV-1-treated patients: Influence of antiretroviral treatment and immunovirological response. HIV Clin Trials. 2001;2:339-45.
26. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving longterm nucleoside analogue therapy. AIDS. 1999;13:1659-67.
27. Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA, Weller IV. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS. 1999;13:735-7.
28. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. [see comments]. Lancet. 1998; 351:867-70.
29. Rakotoambinina B, Medioni J, Rabian C, Jubault V, Jais JP, Viard JP. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J Acquir Immune Defic Syndr. 2001;27:443-9.
30. Galli M, Ridolfo AL, Adorni F, et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2002;29:21-31.
31. Bogner JR, Vielhauer V, Beckmann RA, et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr. 2001;27:237-44.
32. van der Valk M, Gisolf EH, Reiss P, et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 2001;15:847-55.
33. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001;15:1389-98.
34. Kosmiski LA, Kuritzkes DR, Lichtenstein KA, et al. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS. 2001;15:1993-2000.
35. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001;32:130-9.
36. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1999;13:465-71.
37. Dong KL, Bausserman LL, Flynn MM, et al. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr. 1999;21:107-13.
38. Segerer S, Bogner JR, Walli R, Loch O, Goebel FD. Hyperlipidemia under treatment with proteinase inhibitors. Infection. 1999;27:77-81.
39. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study. Lancet. 2001;357:592-8.
40. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS. 1998;12:F167-73.
41. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351:1881-3.
42. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354:1112-5.
43. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 1999;13:2493-505.
44. Behrens G, Schmidt HH, Stoll M, Schmidt RE. ApoE genotype and protease-inhibitor-associated hyperlipidaemia. Lancet. 1999;354:76.
45. Lenhard JM, Croom DK, Weiel JE, Winegar DA. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol. 2000;20:2625-9.
46. Grunfeld C, Doerrler W, Pang M, Jensen P, Weisgraber KH, Feingold KR. Abnormalities of apolipoprotein E in the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1997;82:3734-40.
47. Paganelli R, Mezzaroma I, Mazzone AM, Pinter E, AIuti F. Leptin levels in HIV-positive patients treated with HAART. AIDS. 1999;13:2479.
48. Mooser V, Carr A. Antiretroviral therapy-associated hyperlipidaemia in HIV disease. Curr Opin Lipidol. 2001;12:313-9.
49. Graham NM. Metabolic disorders among HIV-infected patients treated with protease inhibitors: A review. J Acquir Immune Defic Syndr. 2000;25:S4-11.
50. Liang JS, Distler O, Cooper DA, et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med. 2001;7:1327-31.
51. Allan DA, Behrman AJ. Lipid abnormalities in a healthcare worker receiving HIV prophylaxis. Int J STD AIDS. 2001;12:532-4.
52. Zaera MG, Miro O, Pedrol E, et al. Mitochondrial involvement in antiretroviral therapy-related lipodystrophy. AIDS. 2001;15:1643-51.
53. Moyle G. Mitochondrial toxicity hypothesis for lipoatrophy: A refutation. AIDS. 2001;15:413-5.
54. Fauvel J, Bonnet E, Ruidavets JB, et al. An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS. 2001;15:2397-406.
55. Yanovski JA, Miller KD, Kino T, et al. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab. 1999;84:1925-31.
56. Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE. Vascular complications associated with use of HIV protease inhibitors [letter; comment]. Lancet. 1998;351:1958.
57. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. [letter]. [see comments]. Lancet. 1998;351:1328.
58. Vittecoq D, Escaut L, Monsuez JJ. Vascular complications associated with use of HIV protease inhibitors [letter; comment]. Lancet. 1998;351:1959.
59. Eriksson U, Opravil M, Amann FW, Schaffner A. Is treatment with ritonavir a risk factor for myocardial infarction in HIV-infected patients? AIDS. 1998;12:2079-80.
60. Flynn TE, Bricker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med. 1999;131:548.
61. Muise A, Arbess G. The risk of myocardial infarction in HIV-infected patients receiving HAART: A case report. Int J STD AIDS. 2001;12:612-3.
62. Depairon M, Chessex S, Sudre P, et al. Premature atherosclerosis in HIV-infected individuals - Focus on protease inhibitor therapy. AIDS. 2001;15:329-34.
63. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104:257-62.
64. Takase B, Uehata A, Akima T, et al. Endothelium-dependent flowmediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol. 1998;82:1535-9.
65. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101:1899-906.
66. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. [see comments]. N Engl J Med. 1995;332:488-93.
67. Rickerts V, Brodt H, Staszewski S, Stille W. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: The Frankfurt HIV-cohort study. Eur J Med Res. 2000;5:329-33.
68. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-9.
69. Avins AL, Neuhaus JM. Do triglycerides provide meaningful information about heart disease risk. [see comments]. Arch Intern Med. 2000;160:1937-44.
70. Schmitz M, Michl GM, Walli R, et al. Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. J Acquir Immune Defic Syndr. 2001;26:225-35.
71. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 1998;81:18B-25B.
72. Sprecher DL, Pearce GL. How deadly is the "deadly quartet"? A post-CABG evaluation. J Am Coll Cardiol. 2000;36:1159-65.
73. Brunzell JD, Bierman EL. Chylomicronemia syndrome. Interaction of genetic and acquired hypertriglyceridemia. Med Clin North Am. 1982;66:455-68.
74. Perry RC, Cushing HE, Deeg MA, Prince MJ. Ritonavir, triglycerides, and pancreatitis. Clin Infect Dis. 1999;28:161-2.
75. Eng KT, Liu ES, Silverman MS, Berger AR. Lipemia retinalis in acquired immunodeficiency syndrome treated with protease inhibitors. Arch Ophthalmol. 2000;118:425-6.
76. Press N, Montessori V, Bai TR, Montaner J. Respiratory failure associated with the lipodystrophy syndrome in an HIV-positive patient with compromised lung function. Can Respir J. 2001;8:279-82.
77. Saint-Marc T, Touraine JL. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS. 1999;13:2188-9.
78. Moyle G, Baldwin C. Switching from a PI-based to a PI-sparing regimen for management of metabolic or clinical fat redistribution. AIDS Read. 2000;10:479-85.
79. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. [letter]. [see comments]. Lancet. 1998;352:1031-2.
80. Moyle GJ, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard BG. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS. 2001;15:1503-8.
81. Thomas JC, Lopes-Virella MF, Del Bene VE, et al. Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities. Pharmacotherapy. 2000;20:727-34.
82. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA. 2000;284:472-7.
83. Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS. 1999;13:2099-103.
84. Arioglu E, Duncan-Morin J, Sebring N, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. [see comments]. Ann Intern Med. 2000;133:263-74.
85. Ponce-de-Leon S, Iglesias M, Ceballos J, Ostrosky-Zeichner L. Liposuction for protease-inhibitor-associated lipodystrophy. Lancet. 1999;353:1244.
86. Dube MP, Sprecher D, Henry WK, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis. 2000;31:1216-24.
87. Perez A, Wagner AM, Carreras G, et al. Prevalence and phenotypic distribution of dyslipidemia in type 1 diabetes mellitus: Effect of glycemic control. Arch Intern Med. 2000;160:2756-62.
88. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47.
89. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). [see comments]. JAMA. 2001;285:2486-97.
90. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286:2568-77.
91. Fruchart JC, Brewer HB Jr., Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Am J Cardiol. 1998;81:912-7.
92. Goldberg AC. Fenofibrate for the treatment of type IV and V hyperlipoproteinemia: A double-blind, placebo-controlled multicenter US study. Clin Ther. 1989;11:69-83.
93. Miller M. Current perspectives on the management of hypertriglyceridemia. Am Heart J. 2000;140:232-40.
94. Manttari M, Koskinen P, Manninen V, Huttunen JK, Frick MH, Nikkila EA. Effect of gemfibrozil on the concentration and composition of serum lipoproteins. A controlled study with special reference to initial triglyceride levels. Atherosclerosis. 1990;81:11-7.
95. Caslake MJ, Packard CJ, Gaw A, et al. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb. 1993;13:702-11.
96. Guyton JR, Blazing MA, Hagar J, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med. 2000;160:1177-84.
97. Schwenk TL, Fisher M. Hepatitis caused by low-dose sustained-release niacin. J Am Board Fam Pract. 1994;7:242-4.
98. Etchason JA, Miller TD, Squires RW, et al. Niacin-induced hepatitis: A potential side effect with low-dose time-release niacin. Mayo Clin Proc. 1991;66:23-8.
99. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA. 1990;264:723-6.
100. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: Meta-analysis of randomised trials. BMJ. 2000;321:983-6.
101. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol. 1998;81:66B-9B.
102. Dujovne CA, Chremos AN, Pool JL, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. Am J Med. 1991;91:25S-30S.
103. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol. 1988;62:28J-34J.
104. Farnier M, Dejager S. Effect of combined fiuvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group. Am J Cardiol. 2000;85:53-7.
105. Ellen RL, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol. 1998;81:60B-5B.
106. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: An appraisal of their efficacy and safety. Eur Heart J. 1995;16:5-13.
107. Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med. 1993;94:13-20.
108. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA. 1990;264:71-5.
109. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498-511.
110. Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: The role of metabolism-monograph for physicians. Arch Intern Med. 2000;160:2273-80.
111. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med. 2001;344:984-96.
112. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol. 1997;44:190-4.
113. Mastroianni CM, d'Ettorre G, Forcina G, et al. Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia. AIDS. 2001;15:820-1.
114. Murillas J, Martin T, Ramos A, Portero JL. Atorvastatin for protease inhibitor-related hyperlipidaemia. [letter]. AIDS. 1999;13:1424-5.
115. Baldini F, Di Giambenedetto S, Cingolani A, Murri R, Ammassari A, De Luca A. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: A pilot study. AIDS. 2000;14:1660-2.
116. Anonymous. Choice of lipid lowering drugs. Med Lett Drugs Ther. 1998;40:117-22.
117. Churchill DR, Pym AS, Babiker AG, Back DJ, Weber JN. Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-1 infection. Br J Clin Pharmacol. 1998;46:518-9.
118. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med. 1995;333:1528-33.
119. Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, Gonzalez-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS. 2000;14:807-12.
120. Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: A randomized, controlled, open-label, multicentre study. AIDS. 2001;15:1811-22.
121. Ruiz L, Negredo E, Domingo P, et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-Year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr. 2001;27:229-36.
122. Wensing AM, Reedijk M, Richter C, Boucher CA, Borleffs JC. Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels. AIDS. 2001;15:2191-3.
123. Walli RK, Michl GM, Bogner JR, Goebel FD. Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir. Eur J Med Res. 2001;6:413-21.
124. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS. 1999;13:805-10.
125. Martinez E, Garcia-Viejo MA, Blanco JL, et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis. 2000;31:1266-73.
126. Duncombe C. Reversal of hyperlipidemia and lipodystrophy in patients switching therapy to nelfinavir. J Acquir Immune Defic Syndr. 2000;24:78-9.
127. Doser N, Sudre P, Telenti A, et al. Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen. J Acquir Immune Defic Syndr. 2001;26:389-90.
128. Hewitt RG, Shelton MJ, Esch LD. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1 positive patients. [letter]. AIDS. 1999;13:868-9.
129. de Luis DA, Bachiller P, Aller R. Fenofibrate in hyperlipidaemia secondary to HIV protease inhibitors. Fenofibrate and HIV protease inhibitor. Nutrition. 2001;17:414-5.